Սպիրտ

main_info

  • trade_name:
  • Սպիրտ բժշկական
  • dosage:
  • 70%25մլ, 30մլ, 50մլ, 100մլ, 250մլ, 500մլ, 750մլ, 1000մլ, 5000մլ, 10
  • pharmaceutical_form:
  • լուծույթ
  • prescription_type:
  • Առանց դեղատոմսի
  • medicine_domain:
  • Human
  • medicine_type:
  • Allopathic

documents

localization

  • country:
  • Սպիրտ բժշկական
    አርሜኒያ
  • language:
  • አማርኛ

other_info

status

  • source:
  • Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում - Armenia
  • last_update:
  • 31-05-2018

14-8-2018

Neo-Image Candlelight Ltd recalls Thermoglow Stem Wick Chafing fuel & Thermoglow Methanol Gel Chafing Fuel

Neo-Image Candlelight Ltd recalls Thermoglow Stem Wick Chafing fuel & Thermoglow Methanol Gel Chafing Fuel

The recalled products do not have proper hazard labelling as required by the Consumer Chemicals and Containers Regulations, 2001 under the Canada Consumer Product Safety Act. Improper labelling could result in unintentional exposure to these products and lead to serious illness, injury or death.

Health Canada

23-5-2018

95% Ethyl Alcohol Product by Ethanol Extraction: Recall - Due to a Possible Contamination with Methanol

95% Ethyl Alcohol Product by Ethanol Extraction: Recall - Due to a Possible Contamination with Methanol

Methanol,a highly toxic type of alcohol, can cause serious and sometimes fatal damage if ingested by humans or animals.

FDA - U.S. Food and Drug Administration

23-5-2018

Ethanol Extraction Recalls Alcohol Product Because of Possible Health Risk

Ethanol Extraction Recalls Alcohol Product Because of Possible Health Risk

Lake Michigan Distilling Company, LLC of La Porte, Indiana, doing business as Ethanol Extraction, is recalling its 95% Ethyl Alcohol product (“Product”) because of possible contamination with methanol, a highly toxic type of alcohol that can cause serious and sometimes fatal damage if ingested by humans or animals.

FDA - U.S. Food and Drug Administration

14-3-2019


Orphan designation: Treprostinil diethanolamine (oral use), Treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension, 26/08/2005, Positive

Orphan designation: Treprostinil diethanolamine (oral use), Treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension, 26/08/2005, Positive

Orphan designation: Treprostinil diethanolamine (oral use), Treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension, 26/08/2005, Positive

Europe - EMA - European Medicines Agency

14-3-2019


Orphan designation: Treprostinil diethanolamine, Treatment of systemic sclerosis, 15/05/2009, Positive

Orphan designation: Treprostinil diethanolamine, Treatment of systemic sclerosis, 15/05/2009, Positive

Orphan designation: Treprostinil diethanolamine, Treatment of systemic sclerosis, 15/05/2009, Positive

Europe - EMA - European Medicines Agency

28-2-2019

EU/3/09/635 (Unither Therapeutik GmbH)

EU/3/09/635 (Unither Therapeutik GmbH)

EU/3/09/635 (Active substance: Treprostinil diethanolamine) - Transfer of orphan designation - Commission Decision (2019)1743 of Thu, 28 Feb 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000004224

Europe -DG Health and Food Safety

28-2-2019

EU/3/05/310 (Unither Therapeutik GmbH)

EU/3/05/310 (Unither Therapeutik GmbH)

EU/3/05/310 (Active substance: Treprostinil diethanolamine (oral use)) - Transfer of orphan designation - Commission Decision (2019)1742 of Thu, 28 Feb 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000004331

Europe -DG Health and Food Safety